Literature DB >> 18955539

Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.

George R Thompson1, Nathan P Wiederhold, Annette W Fothergill, Ana C Vallor, Brian L Wickes, Thomas F Patterson.   

Abstract

We measured antifungal activity against 128 cryptococcal isolates (86 of C. neoformans and 42 of C. gattii) to determine if differences in serotype susceptibility exist. Contrary to previous results, we found no serotype susceptibility differences. Isavuconazole, posaconazole, and voriconazole demonstrated excellent potency against each isolate and serotype, including isolates with reduced fluconazole susceptibilities.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18955539      PMCID： PMC2612192          DOI： 10.1128/AAC.01216-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Antifungal susceptibility of clinical and environmental isolates of Cryptococcus neoformans to four antifungal drugs determined by two techniques.

Authors:  E M P Moraes; N S Prímola; Júnia Soares Hamdan
Journal:  Mycoses       Date:  2003-06       Impact factor: 4.377

2.  Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group.

Authors:  S Chen; T Sorrell; G Nimmo; B Speed; B Currie; D Ellis; D Marriott; T Pfeiffer; D Parr; K Byth
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

3.  Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan.

Authors:  Y C Chen; S C Chang; C C Shih; C C Hung; K T Luhbd; Y S Pan; W C Hsieh
Journal:  Diagn Microbiol Infect Dis       Date:  2000-03       Impact factor: 2.803

4.  Cryptococcus neoformans variety gattii.

Authors:  T C Sorrell
Journal:  Med Mycol       Date:  2001-04       Impact factor: 4.076

5.  Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C).

Authors:  K J Kwon-Chung; I Polacheck; J E Bennett
Journal:  J Clin Microbiol       Date:  1982-03       Impact factor: 5.948

6.  Epidemiologic differences between the two varieties of Cryptococcus neoformans.

Authors:  K J Kwon-Chung; J E Bennett
Journal:  Am J Epidemiol       Date:  1984-07       Impact factor: 4.897

7.  In vitro antifungal susceptibility of Cryptococcus gattii.

Authors:  Luciana Trilles; Belkys Fernández-Torres; Márcia dos Santos Lazéra; Bodo Wanke; Josep Guarro
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

8.  Clinical and host differences between infections with the two varieties of Cryptococcus neoformans.

Authors:  B Speed; D Dunt
Journal:  Clin Infect Dis       Date:  1995-07       Impact factor: 9.079

9.  Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India.

Authors:  Zia U Khan; Harbans S Randhawa; Tusharantak Kowshik; Anuradha Chowdhary; Rachel Chandy
Journal:  J Antimicrob Chemother       Date:  2007-06-06       Impact factor: 5.790

10.  Damage to yeast cells of Cryptococcus neoformans by voriconazole and fluconazole: a culture and microscopic study.

Authors:  E Brummer; K Kamei; M Miyaji
Journal:  Med Mycol       Date:  1998-08       Impact factor: 4.076
View more
  45 in total

Review 1.  Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.

Authors:  George R Thompson; Nathan P Wiederhold
Journal:  Mycopathologia       Date:  2010-06-05       Impact factor: 2.574

2.  Combination efficacy of voriconazole and amphotericin B in the experimental disease in immunodeficient mice caused by fluconazole-resistant Cryptococcus neoformans.

Authors:  Eriques Gonçalves Silva; Claudete Rodrigues Paula; Amanda Latercia Tranches Dias; Marilene Rodrigues Chang; Luciana da Silva Ruiz; Valderez Gambale; Renato Araujo Prates; Martha Simões Ribeiro
Journal:  Mycopathologia       Date:  2010-10-24       Impact factor: 2.574

3.  Extensive genetic diversity within the Dutch clinical Cryptococcus neoformans population.

Authors:  Ferry Hagen; María-Teresa Illnait-Zaragozí; Jacques F Meis; William H M Chew; Ilse Curfs-Breuker; Johan W Mouton; Andy I M Hoepelman; Lodewijk Spanjaard; Paul E Verweij; Greetje A Kampinga; Ed J Kuijper; Teun Boekhout; Corné H W Klaassen
Journal:  J Clin Microbiol       Date:  2012-03-21       Impact factor: 5.948

4.  Antifungal therapy in a murine model of disseminated infection by Cryptococcus gattii.

Authors:  Enrique Calvo; F Javier Pastor; M Mar Rodríguez; Isabel Pujol; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

5.  Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.

Authors:  K Datta; P Rhee; E Byrnes; G Garcia-Effron; D S Perlin; J F Staab; K A Marr
Journal:  J Clin Microbiol       Date:  2013-06-26       Impact factor: 5.948

6.  A murine model of Cryptococcus gattii meningoencephalitis.

Authors:  George R Thompson; Nathan P Wiederhold; Laura K Najvar; Rosie Bocanegra; William R Kirkpatrick; John R Graybill; Thomas F Patterson
Journal:  J Antimicrob Chemother       Date:  2012-02-29       Impact factor: 5.790

7.  In vitro activity of isavuconazole against clinically isolated yeasts from Chile.

Authors:  Eduardo Álvarez Duarte; Valentina Salas
Journal:  Braz J Microbiol       Date:  2020-07-07       Impact factor: 2.476

8.  Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States.

Authors:  Naureen Iqbal; Emilio E DeBess; Ron Wohrle; Ben Sun; Randall J Nett; Angela M Ahlquist; Tom Chiller; Shawn R Lockhart
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948

9.  A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease.

Authors:  Tran Th Chau; Nguyen H Mai; Nguyen H Phu; Ho D Nghia; Ly V Chuong; Dinh X Sinh; Van A Duong; Pham T Diep; James I Campbell; Stephen Baker; Tran T Hien; David G Lalloo; Jeremy J Farrar; Jeremy N Day
Journal:  BMC Infect Dis       Date:  2010-07-09       Impact factor: 3.090

10.  Cryptococcus gattii: An Emerging Cause of Fungal Disease in North America.

Authors:  Ashwin Dixit; Scott F Carroll; Salman T Qureshi
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.